Proton RT for the Treatment of Pediatric Rhabdomyosarcoma

Status: Recruiting
Phase: Phase 2
Diagnosis: Pediatric Sarcoma
NCT ID: NCT00592592 (View complete trial on ClinicalTrials.gov)
DFCI Protocol ID: 04-188

 

The main purpose of this study is to see if using proton beam radiation therapy instead of photon beam radiation therapy can reduce side effects from radiation treatment for rhabdomyosarcoma. Photon beam radiation is the standard type of radiation for treating most rhabdomyosarcoma and many other types of cancer. Photon beam radiation enters the body and passes through healthy tissue, encounters the tumor, then leaves the body through healthy tissue. A beam of proton radiation enters the body and passes through healthy tissue, encounters tumor, but then stops. This means that less healthy tissue is affected by proton beam radiation than by photon beam radiation.

 

Conducting Institutions:
Dana-Farber Cancer Institute, Children's Hospital Boston, Massachusetts General Hospital, Brigham and Women's Hospital

Overall PI:
Torunn Yock, MD, Massachusetts General Hospital

Site-responsible Investigators:
Karen Marcus, MD, Brigham and Women's Hospital

Contacts:
Massachusetts General Hospital: Cancer Trials Call Center, 877-789-6100
Dana-Farber Cancer Institute: Childrens Hospital Pediatric Clinical Translation Investigation Program CTIP, ctip@partners.org

Eligibility Criteria

Inclusion Criteria: - Patients with biopsy proven newly diagnosed rhabdomyosarcoma. - Patients less than or equal to 21 years of age. - Patients must be treated with a standardly accepted chemotherapy regimen. - May not have metastatic disease unless aged 2-10 with embryonal histology. - Must be willing to receive follow-up care for a minimum of five years after treatment at MGH and annual visits unless it is too difficult to return to MGH for follow-up care. In that event, they must be willing to have their outside medical information released to us to track the results. - Timing of radiation must be according to the IRB protocol upon which the patient is treated within either 35 days of last chemotherapy or surgery. Exclusion Criteria: - Life expectancy of less than 2 years. - Co-morbidities that would make the use of radiation too toxic to deliver safely, such as serious local injury or collagen vascular disease. - Patients who are pregnant - Previous treatment with radiation therapy.
  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms